Harris Associates L P Abb Vie Inc. Transaction History

Harris Associates L P

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $14,395 - $16,810	93 Added 6.64%	1,493 $256,000
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $223,748 - $254,940	-1,400 Reduced 50.0%	1,400 $254,000
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $62,608 - $70,511	-455 Reduced 13.98%	2,800 $433,000
Q2 2023 Aug 14, 2023	BUY	$132.51 - $164.9 $431,320 - $536,749	3,255 New	3,255 $438,000
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $1.99 Million - $2.22 Million	-22,429 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $1.69 Million - $2 Million	-18,871 Reduced 45.69%	22,429 $2.08 Million
Q1 2018 May 15, 2018	SELL	$92.01 - $123.21 $73,608 - $98,568	-800 Reduced 1.9%	41,300 $3.91 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $1.7 Million - $1.86 Million	-18,950 Reduced 31.04%	42,100 $4.07 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $4.26 Million - $5.45 Million	61,050	61,050 $5.43 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Harris Associates L P, based on Form 13F filings with the SEC.

Stay updated on Harris Associates L P with notifications on news.